News

Press Releases:

SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration

December 19, 2017

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases

December 12, 2017

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients

September 28, 2017

SciFluor Life Sciences Announces First Patients Dosed in Retinal Program with Investigational New Drug Application for SF0166 Topical Ophthalmic Solution

October 17, 2016

SciFluor Life Sciences Enters Clinical Trial Stage for Novel Treatment for Retinal Diseases

August 1, 2016

SciFluor Life Sciences Awarded Second U.S. Patent for Integrin αvβ3 (SF0166) Inhibitors Designed for the Topical Treatment of Retinal Disease

March 9, 2016

SciFluor Life Sciences Patented Compound SF0034 Highlighted in Research Published in The Journal of Neuroscience

June 17, 2015

SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman

April 22, 2015

SciFluor Life Sciences Awarded U.S. Patent for KCNQ2/3 Activator Designed for Treatment of Epilepsy and Related Neurological Disorders

Jan. 8, 2015

SciFluor Life Sciences Awarded U.S. Patent for Integrin αvβ3 Inhibitors Designed for the Topical Treatment of Retinal Disease

Dec. 4, 2014

SciFluor Presents Update on Novel KCNQ2/3 activator at Epilepsy Pipeline Conference

Jun. 5, 2014

SciFluor Life Sciences Presents New Preclinical Data Highlighting Lead Program as a More Potent and Selective Treatment for Partial-Onset Seizure

Jun. 25, 2013

Ben C. Askew, Ph.D. Joins SciFluor Life Sciences as Vice President, Research

Jan. 3, 2013

SciFluor News

SciFluor Announces Positive Top-Line Results of Phase 1/2 Study of SF0166 Eye Drops to Treat Wet Age-Related Macular Degeneration
read more >

SciFluor Announces 6 New Patent Issuances Covering the Use of SF0166 Topical Ophthalmic Solution in Retinal Diseases
read more >

SciFluor Announces Positive Results of Phase 1/2 Study of SF0166 Topical Ophthalmic Solution in Diabetic Macular Edema Patients
read more >